Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
clinical trials
11
×
life sciences
national
11
×
national blog main
national top stories
novartis
11
×
raleigh-durham blog main
11
×
raleigh-durham top stories
11
×
san francisco blog main
san francisco top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
abbvie
amgen
gene therapy
cancer
immunotherapy
johnson & johnson
biogen
cancer immunotherapy
eli lilly
gilead sciences
What
roundup
bio
drug
ipo
new
news
approval
biotech
blood
cancer
days
democrats
fda
head
medicines
nash
public
won
abbvie’s
according
acquisitions
advantages
ahead
akcea
alzheimer’s
america
american
amgen
announced
annual
ash
august
bar
biofourmis
biogen
biogen’s
biopharmaceutical
borne
brings
broader
Language
unset
Current search:
novartis
×
national
×
" raleigh-durham top stories "
×
" clinical trials "
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines